公开(公告)号：WO1995013363A1

公开(公告)日：1995-05-18

申请号：PCT/US1994012522

申请日：1994-11-01

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： THE GENERAL HOSPITAL CORPORATION ,  EMERY, David, W. ,  LEGUERN, Christian, A. ,  SACHS, David, H.

IPC: C12N05/00

CPC classification number: C07K16/28 ,  A61K35/26 ,  A61K35/28 ,  A61K38/13 ,  A61K39/001 ,  A61K39/39541 ,  A61K48/00 ,  A61K2035/122 ,  A61K2039/5156 ,  C07K14/70539 ,  A61K2300/00

Abstract: In general, the invention features a method of purifying hematopoietic stem cells from swine, e.g., miniature swine, cord blood. The method includes collecting swine cord blood and purifying the hematopoietic stem cells from at least one other component of the swine cord blood. The swine cord blood hematopoietic stem cells can be used in methods of inducing tolerance in recipient mammals, e.g., humans, of a first species, to grafts obtained from the swine.

Abstract translation: 通常，本发明的特征在于一种从猪（例如微型猪，脐带血）净化造血干细胞的方法。 该方法包括收集猪脐血并从猪脐带血的至少一种其它成分纯化造血干细胞。 猪脐带血造血干细胞可以用于诱导受体哺乳动物（例如人）第一物种对从猪获得的移植物的耐受性的方法。

公开(公告)号：WO1995009236A1

公开(公告)日：1995-04-06

申请号：PCT/US1994010943

申请日：1994-09-28

Applicant: THE GENERAL HOSPITAL CORPORATION ,  HYBRIDON, INC.

Inventor： THE GENERAL HOSPITAL CORPORATION ,  HYBRIDON, INC. ,  MAROTTA, Charles, A. ,  MAJOCHA, Ronald, E. ,  AGRAWAL, Sudhir

IPC: C12N15/11

CPC classification number: A61K31/70 ,  A61K38/1808 ,  A61K38/185 ,  C12N15/113 ,  C12N2310/315 ,  A61K38/18 ,  A61K2300/00

Abstract: The invention provides a composition of matter, comprised of certain oligonucleotides, which inhibit the expression of beta /A4 peptide of Alzheimer's disease and Down's Syndrome, and nerve growth factor (NGF) to reverse morphological changes caused in neuronal cells by beta /A4 peptide. Further, pharmaceutical compositions, kits and methods for treatment of beta /A4 amyloid-induced morphology as well as an assay for screening candidate antisense oligonucleotides effective in treatment of deleterius effects that are visited upon cells by beta /A4 amyloid peptide are described.

Abstract translation: 本发明提供由某些寡核苷酸组成的物质组合物，其抑制阿尔茨海默病和唐氏综合征的β/ A4肽的表达，以及神经生长因子（NGF）以逆转β/ A4肽在神经元细胞中引起的形态学变化。 此外，描述了用于治疗β/ A4淀粉样蛋白诱导的形态的药物组合物，试剂盒和方法以及用于筛选有效治疗由β/ A4淀粉样蛋白肽访问细胞的有害物质效应的候选反义寡核苷酸的测定法。

公开(公告)号：WO1995004829A1

公开(公告)日：1995-02-16

申请号：PCT/US1994008809

申请日：1994-08-05

Applicant: SHISEIDO CO., LTD. ,  THE GENERAL HOSPITAL CORPORATION

Inventor： SHISEIDO CO., LTD. ,  THE GENERAL HOSPITAL CORPORATION ,  TAJIMA, Masahiro ,  OHNUMA, Manami ,  LERNER, Ethan, L.

IPC: C12N15/62

CPC classification number: C07K14/43577 ,  A61K38/00 ,  C07K2319/00

Abstract: A modified maxadilan protein exhibits higher biological activity than native maxadilan from the sand fly Lutzomyia longipalpis. A modified maxadilan fusion protein contains a thrombin cleavage site. This enables the production of the modified maxadilan as a fusion protein and recovery of the modified maxadilan after digestion with thrombin. The modified maxadilan is a potent vasodilator.

Abstract translation: 改良的maxadilan蛋白显示比来自沙蝇Lutzomyia longipalpis的天然maxadilan更高的生物活性。 修饰的maxadilan融合蛋白含有凝血酶切割位点。 这使得生产改性的maxadilan作为融合蛋白，并在凝血酶消化后回收改性的maxadilan。 改性的maxadilan是一种有效的血管扩张剂。

公开(公告)号：WO1994019692A1

公开(公告)日：1994-09-01

申请号：PCT/US1994001712

申请日：1994-02-17

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： THE GENERAL HOSPITAL CORPORATION ,  NISHIMOTO, Ikuo

IPC: G01N33/543

CPC classification number: C07K14/4722 ,  A61K38/00 ,  C07K14/4711 ,  G01N33/6896 ,  Y10S435/975

Abstract: A method of identifying a therapeutic useful for treating or preventing Alzheimer's disease, which method includes the steps of contacting (a) a first molecule containing the couplone portion of APP (SEQ ID NO: 1) with (b) a second molecule containing the amino acid sequence of Go (SEQ ID NO: 2) or an APP-associating region of Go (SEQ ID NOs: 3, 4, or 5), in the presence of a candidate compound; and determining whether the candidate compound interferes with the association of the first and second molecules, such interference being an indication that the candidate compound is a potential Alzheimer's disease therapeutic.

Abstract translation: 鉴定可用于治疗或预防阿尔茨海默病的治疗剂的方法，该方法包括以下步骤：（a）含有APP（SEQ ID NO：1）的偶联子部分的第一分子与（b）含有氨基 Go（SEQ ID NO：2）的酸序列或Go（SEQ ID NO：3,4或5）的APP相关区域，在候选化合物的存在下; 以及确定候选化合物是否干扰第一和第二分子的缔合，这种干扰是候选化合物是潜在的阿尔茨海默病治疗剂的指示。

公开(公告)号：WO1994019482A1

公开(公告)日：1994-09-01

申请号：PCT/US1994001780

申请日：1994-02-22

Applicant: THE GENERAL HOSPITAL CORPORATION ,  THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： THE GENERAL HOSPITAL CORPORATION ,  THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  CALDERWOOD, Stephen, B. ,  BUTTERTON, Joan, R. ,  MEKALANOS, John, J.

IPC: C12P21/06

CPC classification number: A61K39/107 ,  A61K39/00 ,  A61K2039/523 ,  C07K14/245 ,  C07K14/25 ,  C07K14/28 ,  C12N15/74 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/466 ,  Y02A50/472

Abstract: A bacterial cell (preferably a gram-negative, enteric bacterium such as V. cholerae) the chromosome of which contains a DNA sequence encoding a heterologous antigen, which sequence is functionally linked to an iron-regulated promoter such as the irgA promoter of V. cholerae.

Abstract translation: 细菌细胞（优选革兰氏阴性，肠道细菌如霍乱弧菌），其染色体含有编码异源抗原的DNA序列，该序列与铁调节的启动子功能性连接，例如V的irgA启动子。 霍乱弧菌。

公开(公告)号：WO1994017797A1

公开(公告)日：1994-08-18

申请号：PCT/US1994001511

申请日：1994-02-14

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： THE GENERAL HOSPITAL CORPORATION ,  TRAUNER, Kenneth ,  HASAN, Tayyaba

IPC: A61K31/40

CPC classification number: A61K31/40 ,  A61K31/195 ,  A61K41/0071 ,  Y10S514/825

Abstract: A method of treating proliferative diseases of the joint using photoactivatable compounds such as photofrin, benzoporphyrin derivatives or aminolevulinic acid in combination with light of the appropriate wavelength.

Abstract translation: 使用光活化化合物如光卟啉，苯并卟啉衍生物或氨基乙酰丙酸与合适波长的光组合来治疗关节增生性疾病的方法。

公开(公告)号：WO1994016105A1

公开(公告)日：1994-07-21

申请号：PCT/US1994000470

申请日：1994-01-14

Applicant: THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. ,  THE GENERAL HOSPITAL CORPORATION

Inventor： THE PUBLIC HEALTH RESEARCH INSTITUTE OF THE CITY OF NEW YORK, INC. ,  THE GENERAL HOSPITAL CORPORATION ,  LIZARDI, Paul, M. ,  TYAGI, Sanjay ,  LANDEGREN, Ulf, D. ,  KRAMER, Fred, R. ,  SZOSTAK, Jack, W.

IPC: C12Q01/68

CPC classification number: C12Q1/6867 ,  C12Q1/682 ,  C12Q1/6862 ,  C12Q2521/501 ,  C12Q2521/337 ,  C12Q2531/149 ,  C12Q2561/125 ,  C12Q2533/107

Abstract: There are provided nucleic acid hybridization assays for RNA targets using RNA binary probes and a ribozyme ligase that is a stringent RNA-directed RNA ligase. Preferred assays include exponential amplification for signal generation. Tetrahymena ribozyme ligase is a preferred ligase for use in this invention. It may be tethered to hold it close to the ligation junction. One assay according to this invention is a ''tethered ligase chain reaction''. Also provided are kits for performing assays according to the invention.

Abstract translation: 使用RNA二元探针和作为严格的RNA指导的RNA连接酶的核酶连接酶为RNA靶提供核酸杂交测定。 优选的测定包括用于信号产生的指数扩增。 四膜虫核酶连接酶是用于本发明的优选连接酶。 它可能被束缚以使其靠近结扎处。 根据本发明的一个测定是“连接的连接酶链反应”。 还提供了用于进行根据本发明的测定的试剂盒。

公开(公告)号：WO1994010317A2

公开(公告)日：1994-05-11

申请号：PCT/US1993010506

申请日：1993-11-02

Applicant: THE GENERAL HOSPITAL CORPORATION ,  BRIGHAM AND WOMEN'S HOSPITAL

Inventor： THE GENERAL HOSPITAL CORPORATION ,  BRIGHAM AND WOMEN'S HOSPITAL ,  MICHEL, James, L. ,  KASPER, Dennis, L. ,  AUSUBEL, Frederick, M. ,  MADOFF, Lawrence, C.

IPC: C12N15/31

CPC classification number: C07K14/315 ,  A61K47/646 ,  A61K2039/6068 ,  C12N15/70

Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine provides polysaccharide-protein moieties and contain (a) a group B Streptococcus polysaccharide conjugated to (b) a functional derivative of a group B Streptococcus C protein alpha antigen that retains the ability to elicit protective antibodies against group B Streptococcus. The vaccine may contain only one type of such polysaccharide-protein unit or may contain a mixture of more than one type of unit.

Abstract translation: 能够保护受体免受B组链球菌引起的感染的疫苗。 疫苗提供多糖 - 蛋白质部分，并含有（a）与（b）B族链球菌C蛋白α抗原的功能性衍生物缀合的B族链球菌多糖，其保留对B族链球菌引起保护性抗体的能力。 疫苗可以仅含有一种类型的这种多糖 - 蛋白质单元，或者可以包含多于一种类型的单元的混合物。

公开(公告)号：WO1994010300A1

公开(公告)日：1994-05-11

申请号：PCT/US1993010069

申请日：1993-10-20

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： THE GENERAL HOSPITAL CORPORATION ,  BRENT, Roger ,  GYURIS, Jeno ,  GOLEMIS, Erica

IPC: C12N15/10

CPC classification number: C12Q1/6897 ,  A61K38/00 ,  C07K14/4738 ,  C07K2319/00 ,  C07K2319/61 ,  C07K2319/71 ,  C07K2319/80 ,  C12N9/1205 ,  C12N9/16 ,  C12N15/1055 ,  C12Q2565/201

Abstract: Disclosed is a method for determining whether a first protein is capable of physically interacting with a second protein. The method involves: (a) providing a host cell which contains (i) a reporter gene operably linked to a protein binding site; (ii) a first fusion gene which expresses a first fusion protein, the first fusion protein including the first protein covalently bonded to a binding moiety which is capable of specifically binding to the protein binding site; and (iii) a second fusion gene which expresses a second fusion protein, the second fusion protein including the second protein covalently bonded to a weak gene activating moiety; and (b) measuring expression of the reporter gene as a measure of an interaction between the first and the second proteins. Such a determination facilitates the isolation of the gene encoding the interacting protein. Also disclosed herein is recombinant Cdi1 polypeptide, nucleic acid encoding the Cdi1 polypeptide, and uses thereof.

Abstract translation: 公开了一种用于确定第一蛋白质是否能够与第二蛋白质物理相互作用的方法。 该方法包括：（a）提供宿主细胞，其包含（i）与蛋白质结合位点可操作地连接的报告基因; （ii）表达第一融合蛋白的第一融合基因，所述第一融合蛋白包括共价键合到能够特异性结合蛋白结合位点的结合部分的第一蛋白; 和（iii）表达第二融合蛋白的第二融合基因，所述第二融合蛋白包括与弱基因活化部分共价结合的第二蛋白质; 和（b）测量报告基因的表达作为第一和第二蛋白质之间相互作用的量度。 这样的测定有助于分离编码相互作用蛋白的基因。 本文还公开了重组Cdi1多肽，编码Cdi1多肽的核酸及其用途。

公开(公告)号：WO1994009133A1

公开(公告)日：1994-04-28

申请号：PCT/US1993009634

申请日：1993-10-06

Applicant: THE GENERAL HOSPITAL CORPORATION

Inventor： THE GENERAL HOSPITAL CORPORATION ,  KINGSTON, Robert, E. ,  BUNKER, Christopher, Alden

IPC: C12N15/12

CPC classification number: C07K14/005 ,  C07K14/82 ,  C07K2319/00 ,  C07K2319/73 ,  C07K2319/80 ,  C12N15/1055 ,  C12N15/1079 ,  C12N15/62 ,  C12N2795/10322 ,  C12Q1/02 ,  C12Q1/025 ,  C12Q1/68 ,  C12Q1/6897 ,  C12Q1/70 ,  G01N33/5008 ,  G01N33/6803

Abstract: A rapid, simple and inexpensive method to screen and classify proteins as partners of dimeric proteins is described. The method utilizes fusion protein constructs containing a DNA binding domain and complementary dimerization domains from a different protein. According to the method of the invention, protein partner heterodimer formation is detected by the ability of the protein partner to displace formation of DNA binding domain homodimers, and thus reveal a phenotypic change in a bacterial host which was dependent upon maintenance of the DNA binding domain homodimer configuration. The method of the invention may further be used to identify compounds of interest which inhibit such heterodimer formation, and especially to identify compounds which prevent heterodimer formation and activation of oncogenic transcriptional regulatory proteins.

Abstract translation: 描述了将蛋白质筛选和分类为二聚体蛋白质的配偶体的快速，简单和便宜的方法。 该方法利用含有不同蛋白质的DNA结合域和互补二聚化结构域的融合蛋白构建体。 根据本发明的方法，通过蛋白质配偶体取代DNA结合结构域同源二聚体的形成的能力来检测蛋白质伴侣异二聚体形成，从而揭示依赖于DNA结合结构域维持的细菌宿主中的表型变化 同型二聚体配置 本发明的方法还可用于鉴定抑制这种异二聚体形成的感兴趣的化合物，特别是鉴定预防异源二聚体形成和致癌转录调节蛋白激活的化合物。